Scarica l'app Stockscreener
8.58
6.43%
-0.59
Dopo l'orario di chiusura:
8.62
0.04
+0.47%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$9.17
Aprire:
$9.17
Volume 24 ore:
1.27M
Relative Volume:
1.77
Capitalizzazione di mercato:
$585.59M
Reddito:
$46.02M
Utile/perdita netta:
$-70.80M
Rapporto P/E:
-3.0426
EPS:
-2.82
Flusso di cassa netto:
$-1.61M
1 W Prestazione:
-28.50%
1M Prestazione:
-22.35%
6M Prestazione:
-27.53%
1 anno Prestazione:
+29.02%
Intervallo 1D:
$8.56
$9.305
Intervallo di 1 settimana:
$8.56
$11.97
Portata 52W:
$5.855
$30.99
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Nome
Eyepoint Pharmaceuticals Inc
Settore
Industria
Telefono
617-926-5000
Indirizzo
480 PLEASANT STREET, WATERTOWN, MA
Confronta EYPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| EYPT | 8.58 | 585.59M | 46.02M | -70.80M | -1.61M | -2.82 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-01-22 | Iniziato | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Mizuho | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2021-01-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Ripresa | Laidlaw | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
Mostra tutto
Eyepoint Pharmaceuticals Inc Borsa (EYPT) Ultime notizie
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s Stock Reduces -12.58%, Making It A Good Investment - Stocks Register
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint Pharmaceuticals Awards 23,600 Stock Options to New Employees at $9.17 | EYPT Stock News - StockTitan
EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 8.5%What's Next? - MarketBeat
EyePoint Pharmaceuticals : Announces $16.5 Million Monetization of ILUVIEN Royalty with SWK Holdings Corporation - Marketscreener.com
HC Wainwright Has Pessimistic View of EYPT FY2024 Earnings - MarketBeat
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity - Seeking Alpha
Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High? - Yahoo Finance
EyePoint price target lowered to $33 from $38 at Baird - Yahoo Finance
(EYPT) Technical Data - Stock Traders Daily
EyePoint Pharmaceuticals Reports $29.4 Million Third Quarter Net Loss - Vision Monday
EyePoint shares retain Outperform as Baird sees upside in DME and wet AMD opportunities - Investing.com
EyePoint Pharmaceuticals, Inc.’s US$161 Million Public Offering Of Common Stock - Global Legal Chronicle
H.C. Wainwright trims EyePoint stock target, highlights cash runway extension to 2027 - Investing.com
EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $22.00 by Analysts at HC Wainwright - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $33.00 by Analysts at Robert W. Baird - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Raised to $33.00 - MarketBeat
EyePoint Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance Australia
EyePoint Pharmaceuticals Advances in Retinal Therapeutics - TipRanks
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
EyePoint Pharmaceuticals: Q3 Earnings Snapshot - San Francisco Chronicle
EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments - The Manila Times
Federated Hermes, Inc. Expands Stake in EyePoint Pharmaceuticals Inc - GuruFocus.com
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Scrip
With 61% ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) boasts of strong institutional backing - Yahoo Finance
Vanguard Group Inc's Strategic Acquisition in EyePoint Pharmaceu - GuruFocus.com
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 5.4%What's Next? - MarketBeat
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - The Manila Times
EyePoint Pharmaceuticals Announces Successful Closure of Underwritten Public Offering WATERTOWN, Mass., October 31, 2024 – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) recently finalized its underwritten public offering of 14,636,363 shares - Defense World
EYPTEyePoint Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
When (EYPT) Moves Investors should Listen - Stock Traders Daily
EyePoint rises on interim data for mid-stage trial of its diabetic macular edema therapy - MSN
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares - The Manila Times
EyePoint Pharmaceuticals prices $140M share offering - MSN
EyePoint Pharmaceuticals (NASDAQ:EYPT) Sees Strong Trading VolumeWhat's Next? - MarketBeat
EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock? - MSN
Guggenheim maintains Buy on EyePoint with $68 target - Investing.com India
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering - The Manila Times
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering - GlobeNewswire Inc.
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 6.5%Should You Sell? - MarketBeat
EyePoint launches $100 million public stock offering By Investing.com - Investing.com Australia
EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Rating Reaffirmed by Chardan Capital - MarketBeat
Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52% - Simply Wall St
‘Really competitive’ tax breaks keep EyePoint manufacturing in Mass. - The Business Journals
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - MSN
Coinbase Global Inc Cl A (COIN-Q) QuotePress Release - The Globe and Mail
HC Wainwright Reaffirms Buy Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
EyePoint shares hold as analyst reiterates Buy rating By Investing.com - Investing.com South Africa
EyePoint reports positive DURAVYU trial results for DME By Investing.com - Investing.com South Africa
Eyepoint Pharmaceuticals Inc Azioni (EYPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):